Cargando…

Are Drug Eluting Stents Worth Triple Therapy?

Detalles Bibliográficos
Autor principal:	Heidenreich, Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5586481/ https://www.ncbi.nlm.nih.gov/pubmed/28862966 http://dx.doi.org/10.1161/JAHA.117.006983

Ejemplares similares

CURRENT DEVELOPMENTS IN DRUG ELUTING DEVICES: Introductory Editorial: Drug-Eluting Stents or Drug-Eluting Grafts? Insights from Proteomic Analysis
por: Spadaccio, Cristiano, et al.
Publicado: (2017)

Pathogenesis of late in-stent thrombosis after treatment with drug-eluting stents
por: Hao, Hiroyuki
Publicado: (2012)

Comparison of drug-eluting balloon with repeat drug-eluting stent for recurrent drug-eluting stent in-stent restenosis
por: Wang, Guozhong, et al.
Publicado: (2019)

Optimizing the Duration of Dual Antiplatelet Therapy After Implantation of Drug-eluting Coronary Stents
por: Shen, Ying, et al.
Publicado: (2015)

Exploring alternatives to drug-eluting stents: the potential of combining drug coated balloon with bare-metal stents
por: Murai, Kota, et al.
Publicado: (2023)

Stent Optimization Using Adjunctive Balloon Dilatation in the Era of Second-Generation Drug-Eluting Stents
por: Kim, Min Chul, et al.
Publicado: (2017)

State-of-the-Art Stent Technology to Minimize the Risk of Stent Thrombosis and In-Stent Restenosis: Abluminal-Coated Biodegradable Polymer Drug-Eluting Stent
por: Kang, Dong Oh, et al.
Publicado: (2022)

Optimization of Drug Delivery by Drug-Eluting Stents
por: Bozsak, Franz, et al.
Publicado: (2015)

Mid-Term Follow-Up of Drug-Eluting Stenting for In-Stent Restenosis: Bare-Metal Stents versus Drug-Eluting Stents
por: Faramarzi, Negar, et al.
Publicado: (2013)

Revisiting endovascular treatment in below-the-knee disease. Are drug-eluting stents the best option?
por: Spiliopoulos, Stavros, et al.
Publicado: (2018)

Two-year Clinical Outcomes of Patients with Long Segments Drug-Eluting Stents: Comparison of Sirolimus-Eluting Stent with Paclitaxel-Eluting Stent
por: Kim, Ung, et al.
Publicado: (2011)

Is There an Advantage of Ultrathin-Strut Drug-Eluting Stents over Second- and Third-Generation Drug-Eluting Stents?
por: Gherasie, Flavius-Alexandru, et al.
Publicado: (2023)

Ureteral stent technology: Drug-eluting stents and stent coatings
por: Yang, Luo, et al.
Publicado: (2015)

Intracoronary brachytherapy for in-stent restenosis of drug-eluting stents
por: Ohri, Nisha, et al.
Publicado: (2015)

Switching types of drug-eluting stents does not prevent repeated in-stent restenosis in patients with coronary drug-eluting stent restenosis
por: Nojima, Yuhei, et al.
Publicado: (2014)

Drug-eluting metallic stents in urology
por: Kallidonis, Panagiotis S., et al.
Publicado: (2014)

Socioeconomic Inequalities in Quality of Care and Outcomes Among Patients With Acute Coronary Syndrome in the Modern Era of Drug Eluting Stents
por: Yong, Celina M., et al.
Publicado: (2014)

Perioperative management of antiplatelet therapy in patients with drug-eluting stents
por: Dimitrova, G, et al.
Publicado: (2012)

Polymer-free drug-eluting stents versus permanent polymer drug-eluting stents: An updated meta-analysis
por: Chen, Yun-lin, et al.
Publicado: (2019)

Pricing vaccines and drugs in Europe: worth differentiating?
por: Garattini, Livio, et al.
Publicado: (2020)

Reduction of In-Stent Restenosis and Inflammation with One Stent: New Concept of Sirolimus and Ascorbic Acid-Eluting Coronary Stent
por: Ryu, JiWung, et al.
Publicado: (2021)

Outcomes of stenting with overlapping drug-eluting stents versus overlapping drug-eluting and bare-metal stents for the treatment of diffuse coronary lesions
por: Kassaian, SE, et al.
Publicado: (2010)

The efficacy and safety of drug-eluting balloons for the treatment of in-stent restenosis as compared with drug-eluting stents and with conventional balloon angioplasty
por: Oh, Pyung Chun, et al.
Publicado: (2016)

Drug eluting stents: Focus on Cypher™ sirolimus-eluting coronary stents in the treatment of patients with bifurcation lesions
por: Chieffo, Alaide, et al.
Publicado: (2007)

Drug-Eluting Stent as an Option for Intractable In-Stent Coronary Restenosis
por: Hachinohe, Daisuke, et al.
Publicado: (2011)

Advances in drug eluting stents – focus on the Endeavor(®) zotarolimus stent
por: Bridges, Jonathan, et al.
Publicado: (2008)

Efficacy of Triple Anti-Platelet Therapy Including Cilostazol in Acute Myocardial Infarction Patients Undergoing Drug-Eluting Stent Implantation
por: Park, Keun-Ho, et al.
Publicado: (2009)

Is triple antithrombotic therapy a safe option in patients with AF who receive drug-eluting stents?: a review article
por: Alshahrani, Ali, et al.
Publicado: (2023)

The Worthing Experiment
Publicado: (1958)

Worth Attention
Publicado: (1885)

Drug Release Analysis and Optimization for Drug-Eluting Stents
por: Li, Hongxia, et al.
Publicado: (2013)

Hydrocortisone in septic shock: is it worth it?
por: Young, Paul J.
Publicado: (2023)

Functional Nanoarchitectures For Enhanced Drug Eluting Stents
por: Saleh, Yomna E., et al.
Publicado: (2017)

Dual antiplatelet therapy and drug eluting stents: a marriage of convenience
por: Benezet-Mazuecos, Juan, et al.
Publicado: (2007)

Drug-Eluting Stent: A Review and Update
por: Htay, Thein, et al.
Publicado: (2005)

Pathological Perspective of Drug-Eluting Stent Thrombosis
por: Inoue, Katsumi
Publicado: (2012)

Drug-eluting stents: insights into safety and indications
por: Hassan, Walid
Publicado: (2008)

Drug-Eluting Stents: Technical and Clinical Progress
por: Koźlik, Maciej, et al.
Publicado: (2023)

Second Generation Drug-Eluting Stents: A Review of the Everolimus-Eluting Platform
por: Whitbeck, Matthew G., et al.
Publicado: (2013)

Clinical Outcomes of Drug-Eluting versus Bare-Metal In-Stent Restenosis after the Treatment of Drug-Eluting Stent or Drug-Eluting Balloon: A Systematic Review and Meta-Analysis
por: Yang, Yi-Xing, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_u8uj0aisgntmpobntjan033aia